These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 8205843)
21. Immune response to genital papillomavirus infections in women. Prospects for the development of a vaccine against cervical cancer. Gissmann L; Jochmus I; Nindl I; Müller M Ann N Y Acad Sci; 1993 Aug; 690():80-5. PubMed ID: 8396380 [No Abstract] [Full Text] [Related]
22. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264 [TBL] [Abstract][Full Text] [Related]
24. Papillomavirus-like particles for serology and vaccine development. Kirnbauer R Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670 [TBL] [Abstract][Full Text] [Related]
25. [Recombinant therapeutic vaccines against cancer of the uterine cervix]. Berumen J; Villegas N Salud Publica Mex; 1997; 39(4):288-97. PubMed ID: 9381250 [TBL] [Abstract][Full Text] [Related]
26. Re: Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. Bosch FX; Muñoz N; de Sanjosé S; Franco EL; Lowy DR; Schiffman M; Franceschi S; Kjaer SK; Meijer CJ; Frazer IH; Cuzick J J Natl Cancer Inst; 2001 Sep; 93(17):1349-50. PubMed ID: 11535713 [No Abstract] [Full Text] [Related]
27. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Peng S; Frazer IH; Fernando GJ; Zhou J Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699 [TBL] [Abstract][Full Text] [Related]
28. Papillomaviruses: a correlation between immune evasion and oncogenicity? O'Brien PM; Campo MS Trends Microbiol; 2003 Jul; 11(7):300-5. PubMed ID: 12875812 [No Abstract] [Full Text] [Related]
29. HPV vaccine moves into late stage trials. Connett H Nat Med; 2001 Apr; 7(4):388. PubMed ID: 11283639 [No Abstract] [Full Text] [Related]
30. Multistep carcinogenesis and genital papillomavirus infection. Implications for diagnosis and vaccines. Rangel LM; Ramírez M; Torroella M; Pedroza A; Ibarra V; Gariglio P Arch Med Res; 1994; 25(2):265-72. PubMed ID: 7919824 [TBL] [Abstract][Full Text] [Related]
31. [Prospectives and issues of HPV vaccination in France]. Denis F Med Mal Infect; 2005 Jun; 35 Suppl 2():S140. PubMed ID: 15978373 [No Abstract] [Full Text] [Related]
32. The 18th International Papillomavirus Conference. Bonnez W Antivir Ther; 2000 Dec; 5(4):279-83. PubMed ID: 11142623 [No Abstract] [Full Text] [Related]
34. Papillomavirus vaccines: current status and future prospects. Schiller JT; Okun MM Adv Dermatol; 1996; 11():355-80; discussion 381. PubMed ID: 8718484 [No Abstract] [Full Text] [Related]
35. Prospects for a vaccine against human papillomavirus. Hines JF; Ghim S; Schlegel R; Jenson AB Obstet Gynecol; 1995 Nov; 86(5):860-6. PubMed ID: 7566866 [TBL] [Abstract][Full Text] [Related]
36. Specific human papillomaviruses could participate in epidermal hyperproliferation and autoimmune phenomena in psoriasis. Majewski S; Favre M; Orth G; Jablonska S Acta Derm Venereol; 2001; 81(4):312. PubMed ID: 11720190 [No Abstract] [Full Text] [Related]
37. Papillomaviruses: progress for human and veterinary medicine. Onions D Vet J; 1997 Nov; 154(3):171-2. PubMed ID: 9414949 [No Abstract] [Full Text] [Related]
38. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770 [TBL] [Abstract][Full Text] [Related]
39. Synthesis, properties and applications of papillomavirus-like particles. Sapp M; Volpers C; Streeck RE Intervirology; 1996; 39(1-2):49-53. PubMed ID: 8957669 [TBL] [Abstract][Full Text] [Related]